The 2022 Cystic Fibrosis Foundation Golden Ticket

Congratulations to AVECRIS and Nosis Bio, announced July 20 as winners of the 2022 CF Foundation Golden Ticket Program.

Details

Win lab space for a year at Bakar Labs, the new incubator at UC Berkeley’s Bakar BioEnginuity Hub.

The Cystic Fibrosis Foundation is sponsoring a Golden Ticket Competition with Bakar Labs to help CF stand for Cure Found. As part of the CF Foundation’s $500 million Path to a Cure initiative, up to three companies will win a year of free lab and office space at Bakar Labs. The CF Foundation is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply.

Applications are now closed.

The Golden Ticket program is intended to be transformational for companies awarded support.

Selected applicants will be invited to present their company to a select group of Bakar Labs advisors and CF Foundation leadership in person onsite on July 20.

Cystic fibrosis is a genetic disorder that affects the lungs, pancreas, and other organs through mutations in the CFTR gene. The CF Foundation invests more than $225M annually in emerging science and has a long track record of success in facilitating the development of new cystic fibrosis therapies. In addition to lab and office space, companies will have access to the extensive resources of the CF Foundation, including scientific experts and advice, lab/research tools and techniques, an extensive patient registry/database, clinical trial design support, and a Therapeutic Development Network of over 90 clinical trial sites in the US. Be a part of history by helping to cure this devastating disease.

Timeline

Applications are due by Monday, June 6.

Applicants on the shortlist will be notified by Wednesday, June 29.

The shortlist will present to the judging panel on Wednesday, July 20.

The winners will be announced after the in-person pitch session on July 20.

Eligibility

This competition is open to life science entrepreneurs who are developing and intend to commercialize genetic therapies for cystic fibrosis or related technologies to deliver, enable, or accelerate such therapies.

Companies with university affiliation are eligible; so are companies that have no university affiliation.

Both incorporated and teams that have yet to incorporate are eligible.

Companies seeking seed-stage through Series A funding are eligible.

We are looking for companies for whom winning a Golden Ticket will significantly impact their ability to advance their company.

We intend that this lab space be used by the winning company as its primary site of operations.